Investors & Media

diaDexus Mission
diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Corporate Profile

diaDexus was formed in 1997 as a joint venture by SmithKline Beecham and Incyte. SmithKline Beecham granted diaDexus an exclusive license to certain diagnostic intellectual property, and Incyte contributed free access to its databases.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value.

diaDexus' lead product, the PLAC^® Test, is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. A substantial body of evidence including over 50 articles and abstracts from peer reviewed journals and conferences support Lp- PLA₂ as a cardiovascular risk marker that provides new information over and above traditional risk factors. Click here to see a copy of the diaDexus annotated bibliography.

In addition to developing and marketing the PLAC Test, diaDexus owns or has exclusively licensed patents or patent applications covering hundreds of novel molecular targets associated with cancer. The company is developing simple blood tests to detect early stage cancer in otherwise healthy individuals, with the most advanced diagnostic development targeting detection of ovarian cancer. Furthermore, diaDexus' oncology prognostics program leverages genomic and nucleic acid technological expertise, with the goal of improving the prognosis and staging of breast, colorectal and other cancers.

diaDexus is located in South San Francisco, California and currently employs 70 people.

If you would like more information, please contact us through our Inquiries page.